vs
合众银行（FSBC）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.3倍（$45.1M vs $35.5M），合众银行净利率更高（41.3% vs -304.2%，领先345.5%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 21.3%）
合众银行是总部设在美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构，截至2025年为美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的银行。它旗下核心运营实体为美国银行全国协会，以US Bank品牌开展业务，提供银行、投资、抵押等金融服务。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
FSBC vs RXRX — 直观对比
营收规模更大
FSBC
是对方的1.3倍
$35.5M
净利率更高
FSBC
高出345.5%
-304.2%
两年增速更快
RXRX
近两年复合增速
21.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $35.5M |
| 净利润 | $18.6M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | — | -304.8% |
| 净利率 | 41.3% | -304.2% |
| 营收同比 | — | 681.7% |
| 净利润同比 | 42.0% | 39.6% |
| 每股收益（稀释后） | $0.87 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSBCRXRX
| Q1 26 | $45.1M | — | ||
| Q4 25 | $43.5M | $35.5M | ||
| Q3 25 | $41.3M | $5.2M | ||
| Q2 25 | $38.3M | $19.2M | ||
| Q1 25 | $35.3M | $14.7M | ||
| Q4 24 | $35.2M | $4.5M | ||
| Q3 24 | $31.8M | $26.1M | ||
| Q2 24 | $30.7M | $14.4M |
净利润FSBCRXRX
| Q1 26 | $18.6M | — | ||
| Q4 25 | $17.6M | $-108.1M | ||
| Q3 25 | $16.3M | $-162.3M | ||
| Q2 25 | $14.5M | $-171.9M | ||
| Q1 25 | $13.1M | $-202.5M | ||
| Q4 24 | $13.3M | $-178.9M | ||
| Q3 24 | $10.9M | $-95.8M | ||
| Q2 24 | $10.8M | $-97.5M |
毛利率FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 59.8% | ||
| Q3 25 | — | -183.8% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -48.0% | ||
| Q4 24 | — | -181.4% | ||
| Q3 24 | — | 53.7% | ||
| Q2 24 | — | 36.2% |
营业利润率FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | 52.9% | -304.8% | ||
| Q3 25 | 53.8% | -3327.6% | ||
| Q2 25 | 52.4% | -916.8% | ||
| Q1 25 | 52.0% | -1297.9% | ||
| Q4 24 | 55.1% | -4042.4% | ||
| Q3 24 | 48.0% | -377.1% | ||
| Q2 24 | 49.4% | -697.4% |
净利率FSBCRXRX
| Q1 26 | 41.3% | — | ||
| Q4 25 | 40.6% | -304.2% | ||
| Q3 25 | 39.6% | -3135.3% | ||
| Q2 25 | 37.9% | -894.2% | ||
| Q1 25 | 37.1% | -1373.3% | ||
| Q4 24 | 37.9% | -3935.5% | ||
| Q3 24 | 34.4% | -367.5% | ||
| Q2 24 | 35.2% | -676.6% |
每股收益（稀释后）FSBCRXRX
| Q1 26 | $0.87 | — | ||
| Q4 25 | $0.83 | $-0.17 | ||
| Q3 25 | $0.77 | $-0.36 | ||
| Q2 25 | $0.68 | $-0.41 | ||
| Q1 25 | $0.62 | $-0.50 | ||
| Q4 24 | $0.61 | $-0.56 | ||
| Q3 24 | $0.52 | $-0.34 | ||
| Q2 24 | $0.51 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $644.4M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $458.5M | $1.1B |
| 总资产 | $5.0B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资FSBCRXRX
| Q1 26 | $644.4M | — | ||
| Q4 25 | — | $743.3M | ||
| Q3 25 | — | $659.8M | ||
| Q2 25 | — | $525.1M | ||
| Q1 25 | — | $500.5M | ||
| Q4 24 | — | $594.4M | ||
| Q3 24 | — | $427.6M | ||
| Q2 24 | — | $474.3M |
总债务FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $9.6M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | — | $14.2M | ||
| Q1 25 | — | $16.4M | ||
| Q4 24 | — | $19.0M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $22.9M |
股东权益FSBCRXRX
| Q1 26 | $458.5M | — | ||
| Q4 25 | $445.8M | $1.1B | ||
| Q3 25 | $431.3M | $1.0B | ||
| Q2 25 | $416.7M | $919.1M | ||
| Q1 25 | $406.5M | $933.9M | ||
| Q4 24 | $396.6M | $1.0B | ||
| Q3 24 | $389.9M | $524.6M | ||
| Q2 24 | $380.5M | $584.4M |
总资产FSBCRXRX
| Q1 26 | $5.0B | — | ||
| Q4 25 | $4.8B | $1.5B | ||
| Q3 25 | $4.6B | $1.4B | ||
| Q2 25 | $4.4B | $1.3B | ||
| Q1 25 | $4.2B | $1.3B | ||
| Q4 24 | $4.1B | $1.4B | ||
| Q3 24 | $3.9B | $726.5M | ||
| Q2 24 | $3.6B | $775.9M |
负债/权益比FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.04× | ||
| Q2 24 | — | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | $72.6M | $-46.1M | ||
| Q3 25 | $18.8M | $-117.4M | ||
| Q2 25 | $17.8M | $-76.4M | ||
| Q1 25 | $15.5M | $-132.0M | ||
| Q4 24 | $51.8M | $-115.4M | ||
| Q3 24 | $17.5M | $-59.2M | ||
| Q2 24 | $16.0M | $-82.2M |
自由现金流FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | $71.4M | $-47.3M | ||
| Q3 25 | $18.6M | $-117.6M | ||
| Q2 25 | $17.5M | $-79.6M | ||
| Q1 25 | $15.4M | $-133.8M | ||
| Q4 24 | $51.2M | $-116.7M | ||
| Q3 24 | $17.3M | $-63.8M | ||
| Q2 24 | $15.8M | $-83.4M |
自由现金流率FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | 164.3% | -133.1% | ||
| Q3 25 | 45.0% | -2272.5% | ||
| Q2 25 | 45.8% | -413.9% | ||
| Q1 25 | 43.5% | -907.4% | ||
| Q4 24 | 145.5% | -2567.7% | ||
| Q3 24 | 54.5% | -244.6% | ||
| Q2 24 | 51.6% | -578.5% |
资本支出强度FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | 2.8% | 3.5% | ||
| Q3 25 | 0.5% | 4.7% | ||
| Q2 25 | 0.6% | 16.4% | ||
| Q1 25 | 0.3% | 12.4% | ||
| Q4 24 | 1.8% | 28.6% | ||
| Q3 24 | 0.7% | 17.5% | ||
| Q2 24 | 0.7% | 8.2% |
现金转化率FSBCRXRX
| Q1 26 | — | — | ||
| Q4 25 | 4.12× | — | ||
| Q3 25 | 1.15× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.18× | — | ||
| Q4 24 | 3.89× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.49× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSBC
| Net Interest Income | $43.5M | 96% |
| Noninterest Income | $1.6M | 4% |
RXRX
暂无分部数据
